The association between peroxisome proliferators-activated receptor g (PPARg) Pro12Ala polymorphism and colorectal cancer (CRC) risk is still controversial. A meta-analysis was performed.
Background
Colorectal cancer (CRC) is a common digestive tumor; the incidence of CRC is just lower than gastric and esophageal cancer. More than one million new cases of CRC were diagnosed globally each year [1] . CRC is becoming a very urgent public health concern, especially in the developed countries. In USA, the incidence rate and mortality rate of CRC ranked third among all tumors in both men and women [2] . Body mass index, height, smoking status, and alcohol use have been reported to be associated with CRC risk [3] . However, the pathogenesis of CRC is still uncertain. Identification of related genetic variants could elucidate mechanisms underlying this disease.
Peroxisome proliferators-activated receptors (PPAR), which have PPARa, PPARb/d and PPARg, are members of the nuclear receptor superfamily of ligand-activated transcription factors [4] . Due to its association with many human cancers such as colon, thyroid, breast, and prostate, PPARg has been suggested to be an attractive target for cancer therapy [4] . Although the PPARg nuclear receptor pathway was involved in cancer development, it might appear to have both oncogenic and tumor suppressor functions. Sarraf et al. showed that ligand activation of PPARg in colon cancer cells could cause a considerable reduction in linear and clonogenic growth, increase expression of carcinoembryonic antigen, and the reversal of many gene expression events specifically associated with colon cancer [5] . However, Saez et al. suggested that PPARg activation may provide a molecular link between a high-fat diet and increased risk of CRC [6] .
A common polymorphism in the PPARg, CCA®GCA, causing a Pro®Ala substitution at codon 12 (Pro12Ala), has been reported. The Pro12Ala polymorphism has been suggested to be associated with decreased receptor activity, lower body mass index, and improved insulin sensitivity [7] . The Pro®Ala change might cause a conformational change in the PPARg protein, and thus affect its activity. Several studies have reported the association between PPARg Pro12Ala polymorphism and CRC risk [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . However, the results were still equivocal. Recently, a meta-analysis with nine studies found that this polymorphism was not associated with CRC risk [23] . However, six case-control studies were published and not all studies supported that result. Therefore, we performed a meta-analysis of all eligible studies to evaluate the association between PPARg Pro12Ala polymorphism and CRC risk.
Material and Methods

Material
We conducted a literature search using PubMed, EMBASE, and Cochran databases. The following terms were used: "colorectal neoplasms'' or "colorectal cancer") and ("PPARg" or "peroxisome proliferators-activated receptor g"). The last search was updated on December, 2014. All searched studies were retrieved and only published studies with full-text articles were included. In duplicate samples, only the largest study was used in this research.
Inclusion/exclusion criteria
The inclusion criteria was as follows: (1) a case-control study or a cohort study; (2) the study evaluated the association between PPARg Pro12Ala polymorphism and CRC risk; (3) the PPARg Pro12Ala genotypes were provided.
The exclusion criteria were as follows: (1) animal studies; (2) not relevant to CRC or PPARg; (3) reviews or abstracts; (4) not offer enough data.
Data extraction
Two authors extracted the following data: first author, year, race, sample size, and genotype distribution. The disagreements were resolved by consensus.
Statistical analysis
Statistical analysis was all conducted using Stata software 11.0 (StataCorp, College Station, Texas, USA). HWE test in healthy control group was conducted using c 2 test. Odds ratio (OR) with a 95% confidence interval (CI) was presented for dichotomous data, and significance level was 0.05. Dominant model, recessive model, and additive model were used in this meta-analysis. Q-statistic and I 2 -statistic were used to measure statistical heterogeneity and significance level was 0.10. Effect model selection was on the basis of heterogeneity test. Fixedeffect models was selected when no significant heterogeneity, otherwise we used the random-effects model. Subgroup analyses were carried out based on race and cancer site. To evaluate the reliability of the results, one-way sensitivity analyses and cumulative meta-analysis were performed. Publication bias was investigated by the method of Egger's test. The twosided P<0.05 was considered statistically significant.
Results
Eligible studies Figure 1 shows the study selection procedure. Based on the inclusion and exclusion criteria, 15 studies including 13575 cases and 17085 controls were included in our meta-analysis. Only three studies were performed in Asian populations, while other studies were performed in Caucasian populations. The characteristics of the included studies are listed in Table 1 .
Quantitative synthesis
Result of this meta-analysis suggest that PPARg Pro12Ala polymorphism was significantly associated with a reduced risk of CRC in dominant genetic model (OR=0.90; 95% CI 0.83-0.98; P=0.01; Figure 2 Table 2 .
To evaluate the reliability of the results, we conducted cumulative meta-analysis by pooling the data, and each time one study was added. The results showed that the pooled ORs tended to be stable ( Figure 3) . We also performed the oneway sensitivity analysis by omitting studies one at a time. We found that any single study did not influence the pooled OR, suggesting that the results of this meta-analysis were robust (Figure 4) . Moreover, no significant publication bias was found by funnel plot ( Figure 5 ) and Egger's test (P=0.12) 
Discussion
PPARg Pro12Ala polymorphism has been reported to be associated with breast cancer, gastric cancer, and inflammatory bowel disease [24] [25] [26] . Lu et al. suggested that PPARg Pro12Ala polymorphism was not associated with CRC risk [23] . However, a previous meta-analysis found that PPARg Pro12Ala polymorphism might be a protective factor for CRC [26] . Thus, we did Table 2 . Meta-analysis of association between the PPARg Pro12Ala polymorphism and CRC risk.
P OR and P Q refer to the significance levels of the odds ratio and Q-test of heterogeneity, respectively. 
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License this update meta-analysis to find the association between PPARg Pro12Ala polymorphism and CRC risk. We found that PPARg Pro12Ala polymorphism was significant associated with CRC risk, suggesting that PPARg Ala allele carriers had reduced CRC risk compared to PPARg Pro allele carriers. Furthermore, we found that this effect was only existed in Caucasians but not in Asians, suggesting a possible influence among different genetic backgrounds and environmental exposures, but these were only studies with Asians. More studies with Asians are needed to further investigate the association between PPARg Pro12Ala polymorphism and CRC risk. Results from this meta-analysis found that PPARg Pro12Ala polymorphism was only associated with colon cancer. No significant association was found between PPARg Pro12Ala polymorphism and rectal cancer. It has been suggested that PPARg activity was higher in the distal colon [27] ; it is possible that the Ala/Ala+Pro/Ala genotypes had the greatest effect in the segment of the colon with the least PPARg activity [28] .
Ligands for the PPARg have proven to be effective in preclinical models of CRC. Tanaka and coworkers indicated that administration of the PPARg ligand troglitazone significantly reduces the number of aberrant crypt foci (ACF) lesions [29] . Aires et al. found that the combination of resveratrol with a PPARg agonist could be a promising pharmacological approach for treatment of CRC [30] . Thus, PPARg agonists combined with other chemotherapy drugs or other targeted therapies are worth pursuing in the treatment of CRC [31] [32] [33] [34] [35] [36] .
There were some limitations in this meta-analysis. First, the number of included studies was moderate. Therefore, the results could be influenced by random error. Second, CRC is a multifactorial disease, but the interactions among gene-environment and gene-gene were not considered in this metaanalysis. Third, other factors such as gender or diet habit may participate in the progression of CRC. However, we did not conduct subgroup analysis by these factors due to limited data.
Conclusions
In summary, this study suggested that PPARg Pro12Ala polymorphism was a protective factor of CRC.
Disclosure of conflict of interest
None. 
